anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention comprises 6-chloro-7-sulphamyl-3:4-dihydro-1:2:4-benzothiadiazine-1:1 -dioxide of the formula :- &lt;FORM:0847064/IV(b)/1&gt; and its alkali metal salts, and the preparation thereof by reacting 5-chloro-2:4-disulphamylaniline or an addition or alkali metal salt thereof with formaldehyde in approximately equimolar proportions of the reactants and, if desired, converting the product, when an alkali metal salt, into the free compound, or, when the free compound, into an alkali metal salt.  The formaldehyde may be used in the form of a polymer or reactive functional derivative.ALSO:Pharmaceutical compositions comprise 6-chloro-7-sulphanyl-3:4-dihydro-1:2:4-benzothiadiazine or an alkali metal salt thereof in admixture with an inert pharmaceutical carrier suitable for enteral or parenteral administration.  Suitable carriers are benzyl alcohols, cholesterol, gelatine, gums, lactose, magnesium stearate, polyalkylene glycols, petroleum jelly, starches, talc, vegetable oils or any other known carriers for medicaments.  Other therapeutic substances may be incorporated, such as hypotensive agents like Rauwoldfia or Veratrum alkaloids (e.g. deserpidine, germine, protoveratrine, rescinnamine or reserpine), synthetic hypotensive compounds like hydralazine or ganglionic blockers like chlorisondamine.  They may be sterilised and/or contain auxillary substances like emulsifying, preserving, stabilising and wetting agents, salts for varying the osmotic pressure or buffers, and may take the form of capsules, dragees, emulsions, solutions, suspensions or tablets.  The compositions have a diuretic and natriuretic effect.
The invention relates to a traditional Chinese medicine composition for treating bronchial asthma and acute and chronic bronchopneumonia, which is prepared from the following raw materials, by weight, 25-35 g of herba Humuli Scandentis (scandent hop) and 25-35 g of Malandan (autumn sarcandra herb), wherein the bronchial asthma is located in the lung and causes the disease, and the treatment is carried out only by clearing heat and detoxicating after exogenous wind-cold heat without timely treatment. The prescription of the invention is created according to the theory of the method of eliminating diarrhea by division. The &#34;separate-elimination-and-release&#34; method is developed from the &#34;sum-and-method&#34; in the eight methods of traditional Chinese medicine, namely, the pungent-opening bitter-release drugs are used for dredging qi-flowing, regulating qi and resolving depression, reaching the triple energizer, and opening the way of regulating qi and water to remove pathogenic factors and clear damp-heat of the triple energizer. Wherein, the decoction for warming gallbladder is the first party of the method of eliminating diarrhea by dividing into two parts, and the prescription of the invention is based on the combination of the prescription and the experience of many years of clinical experience. Herba Humuli Scandentis (herba Humuli Scandentis) in the recipe is bitter, sweet and cold in nature. The Chinese medicinal composition has the functions of liver, lung, large intestine and bladder meridian, mainly treating clearing heat and detoxicating, promoting diuresis and removing blood stasis, and the marangoni (autumn fish) has bitter taste, cold nature and entering heat meridian, mainly treating blood cooling and hemostasis, clearing heat and promoting diuresis, detoxifying and detumescence, has special efficacy and quick response, has the effective rate of 90 percent for bronchial asthma and acute and chronic bronchopneumonia after clinical application, has the cure rate of 80 percent, and has remarkable effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition for the oral cavity, which is highly safe and effectively prevents or ameliorates a foul breath.  &lt;P&gt;SOLUTION: The composition for the oral cavity comprises an extract extracted from a roasted material prepared by roasting bran obtained from seeds of at least one kind of plant. The bran is rice bran. The amount of the extract extracted from the roasted material mixed is 0.1-20 wt.%. The composition comprises a propolis extract besides the extract extracted from the roasted material. The amount of the propolis extract mixed is 0.1-20 wt.%. The composition comprises a crude medicine having hemostatic and/or antiphlogistic and anti-inflammatory effect, its extract or processed material.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention relates to a rank-based user-to-user and user-to-venue matchmaking. A user profile is created on a user device through a software application or website. The user can generate temporary points by performing various temporary points attributing actions as described above. The temporary points will become permanent points after real-world authentication process, the user may perform some predefined real-world activities to directly attribute points to the permanent points. The permanent points determine the rank or status of the user profile. Further, the user based on his/her user profile is enabled to view/match another user&#39;s profile. The real-world authentication and various other points attributing actions performed by a user have certain virtual or real-world benefits to the user.
The invention relates to a method of treating chronic granulomatous disease through Hematopoietic stem cell (HSC) transplantation. The method comprises the steps of administering stem cell mobilization agent to human such that the target stem cell population migrates from host niches into the subject&#39;s blood. The target stem cells are removed from blood and administering the therapeutic stem cells to human and said therapeutic stem cells are engineered to express gp91phox. The steps are repeated multiple times i.e. at least four times. The mobilization agents used in the invention are granulocyte-colony stimulating factor and AMD3100. The method of HSC transplantation is effective in treatment of chronic granulomatous disease.
Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington&#39;s chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.
Disclosed is an application of piceatannol-3&#39;-O-β-D-glucopyranoside in the preparation of medicaments for improving microcirculation block. The medicaments comprise piceatannol-3&#39;-O-β-D-glucopyranoside of formula (I) as active ingredients and one or more pharmaceutically acceptable additives, especially of gastrodine and/or water soluble cyclodextrin derivatives, or PEG400 and mannitol. The invention also discloses applications of piceatannol-3&#39;-O-β-D-glucopyranoside as active ingredients in the preparation of medicaments for improving block induced by brain microvascular injury and/or block induced by ischemical reperfusion injury and/or block induced by leucocyte adherence and/or block induced by peroxides. The invention tests the effects of medicaments by tail intravenous injection with Kunming normal mice and model mice with microcirculation block induced artificially. The capillary vessel net and the shrinkage of arteriole and venule are observed under microcirculation microscope. The test shows that: the medicament has obvious expansion effect on blood vessels of the normal mice, can evidently antagonize the shrinkage of arteriole and venule and the reduction of the open number of capillary vessel net of the model mice with microcirculation block, and can obviously confront the blood flow slowing.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatology and maxillofacial surgery, and can be used in the treatment of patients with abscessed boils of the upper and lower areas of the face. Method of treatment includes treating the site of inflammation with an antiseptic solution, removing the purulo-necrotic mass with a syringe and applying a dressing with an ointment. Used a disposable sterile syringe &#34;Luer&#34;, with a needle from the kit previously make a puncture in the center of the infiltrate. Then the syringe is cut off the end part of the cylinder along the first mark of the graduated scale and attached to it a perforated silicone gasket, whose diameter is 2 mm larger than the diameter of the syringe. Use a syringe as a vacuum extractor to completely absorb the purulo-necrotic stem, purulent contents of the pustule, and obtain a single drop of blood. Resulting cavity is then washed with a 3 % hydrogen peroxide solution and an aqueous solution of 0.05 % chlorhexidine. On the inflammatory infiltrate area, 70 % alcohol compress is applied for 15–20 minutes every 2–3 hours for 2 days. Overnight, put a dressing with saline solution for 3 days. From 4 to 7 days impose ointment dressings with &#34;Levomekol&#34; with an interval of 1 day. Conducted also a standard course of antibiotic therapy, indicated for pyoinflammatory diseases of the maxillofacial area.EFFECT: method of treatment is simple and convenient to use, it allows the most effective treatment of abscessed boils with minimization of the operating injury of the soft tissues of the upper and lower areas of the face.1 cl, 2 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means and a method for regulating immune response.  &lt;P&gt;SOLUTION: The new antibodies specifically recognizing a discrete population of human dendritic cells (DC) and methods of isolating the DC, using the antibodies are provided. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding the antibodies are provided. Also provided are vectors comprising the polynucleotides as well as host cells transformed therewith and their use in the production of the antibodies. Additionally, polypeptides comprising a domain of the binding site of the aforementioned antibodies, or an antigen or epitope described above and at least one further, preferably functional domain as well as polynucleotides encoding such polypeptides are described. Furthermore, vectors comprising the polynucleotides, host cells transfected with the polynucleotide or vector and their use for the preparation of the above-described polypeptides are provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a platform for rehabilitative exercise of a patient as well as an entertainment device.  &lt;P&gt;SOLUTION: This signal communication system is equipped with an operation sensor that communicates with an actuator of a robotic apparatus and is attached to a human for measuring his or her physical movements. The operation sensor communicates with a power source and a transceiver. The transceiver communicates with a central processing unit of the robotic apparatus. The central processing unit receives and processes a sensor signal and communicates with the actuator about the input detected with the sensor. The sensor detects an input of a position, speed, acceleration, and power of the human and relates the measured movements of the human to movements of the robotic apparatus.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention relates to methods for increasing the safety of laboratory-produced cellular products ( &#34;tissue engineered products&#34;  (TEP)). The increased safety of such products is achieved by preventing the formation of tumors. The present invention provides a plurality of methods therefor which are based on the irradiation of the TEPs. This irradiation inactivates mitotic cells in the TEP, while the biological functions of the TEP are at least substantially preserved. Some methods of the present invention also include regeneration of the TEP following irradiation. The present invention makes it possible to produce TEPs with no resulting tumor formation, but which nevertheless exhibit biological functions and are therefore ideally suited to transplantation or drug development.
NEW MATERIAL:An oxacephamycin derivative shown by the formula I [R is a group shown by the formula II (R&lt;1&gt; is H, acyl, loweralkanesulfonyl, or arylsulfonyl; R&lt;2&gt; is H or halogen), cyanomethylthioacetyl, etc.] and its pharmaceutically acceptable salt. EXAMPLE:7beta-Cyanomethylthioacetamido-7-alpha-methoxy-3(1-methyl-1H-t etrazole-5- yl)thiomethyl-1-oxadethia-cephem-4-carboxylic acid. USE:An antibacterial agent. Having improved antibacterial activity on a wide range of bacteria. Suitable for oral or parenteral administration. PROCESS:For example, a compound shown by the formula III (M is COOH protecting group or salt-forming group) is reacted with an acid shown by the formula IV or its reactive derivative, and, if necessary, the protecting group is removed, to give a compound shown by the formula I or its salt.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new CD33-like protein, to provide an isolated nucleic acid molecule which encodes the CD33-like protein, to provide a recombinant vector containing the nucleic acid molecule, and to provide a host cell formed by being immunologically treated with the recombinant vector.  &lt;P&gt;SOLUTION: This isolated nucleic acid molecule contains a nucleic acid molecule having a specific sequence which encodes the CD33-like protein or a polypeptide fragment of the protein. The recombinant vector contains the nucleic acid molecule. The host cell is formed by being genetically treated with the recombinant vector. The CD33-like protein or the polypeptide fragment is produced by a recombination technique in the host cell.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To contribute to audit for the amount of medicines having the same component to be prescribed to a patient, and audit whether a prescription order is suitable to the state of the patient or not.  &lt;P&gt;SOLUTION: Medicine item data including administration units stored in a unit conversion master 107 is retrieved to specify administration units of medicine items, administration unit conversion data including conversion coefficients for converting medicine names shown in medicine data and the dosage of medicines shown in a prescription order to dosage of administration units shown in medicine item data stored in a medicine item master 108 is retrieved. Based on the specified administration units, the daily dosage of each medicine item is calculated to generate display data for the calculated daily dosage of every medicine item. The daily dosage is adjusted with a physical data coefficient based on the physical feature of the patient and a reference adjustment coefficient based on the clinical result of the patient to generate a final administration reference value. Further, a determination reference table for daily dosage is formed to determine whether the daily dosage of medicines are appropriate or not.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To provide a coronary vasodilator containing a piperidine derivative as an active component. CONSTITUTION:The objective coronary vasodilator can be produced by using at least one compound selected from the compounds of formulas I, II and III as an active component. The compounds of formulas I, II and III can be produced by extracting fruit of Piper longum (a plant of Piperaceae family) with a proper solvent and purifying the extract by column chromatography. Since the compounds of formula I, II and III have activity to dilated coronary vessel (blood vessel of heart) of mammal, it can be used as a coronary vasodilator and is useful for the remedy of myocardial infraction, etc. These substances exhibit calmodulin-inhibiting activity. Various physiological phenomena of eucaryote are controlled by calcium ion (Ca&lt;++&gt;) and calmodulin is a Ca&lt;++&gt;-receptor protein widely distributed in eucaryote and participating in various physiological phenomena dependent upon Ca&lt;++&gt;. Accordingly, the compound of formula can be used also as various biochemical reagents.
PURPOSE:To obtain an adsorbent having excellent adsorption performance for endotoxin by dispersing or dissolving silicone oil or silicone polymer having specified mol.wt. in an org. solvent and depositing the liquid on the surface of an inorg. material to constitute a composite material. CONSTITUTION:Endotoxin is a lipopolysaccharide and is a typical exothermic matter. When blood contaminated with endotoxin is introduced into a human body, endotoxin causes by-product such as fever. Therefore, contamination of medicine with endotoxin is severely inspected. By providing a composite material having excellent adsorption performance for endotoxin, endotoxin-free water can be efficiently produced at a low cost and endotoxin in proteins can be removed at a low cost. Namely, silicone oil or silicone polymer having &gt;=500 mol.wt. is dispersed or dissolved in an org. solvent and deposited on the surface of an inorg. material to constitute the composite material.
An article, for example a dental point, formed of a hydrophilic plastics material is capable of undergoing controlled radial expansion (d&lt;SB&gt;1&lt;/SB&gt; to d&lt;SB&gt;2&lt;/SB&gt;) upon hydration by aqueous media including body fluids without appreciable axial expansion. The hydrophilic plastics material is pre-stressed by application of pressure to its unhydrated form at a temperature in the range 100 to 160{C. It is then cooled to 40{C or less before release of the applied pressure. After cooling, the material may be machined to shape. Alternatively, pre-stressing can be carried out after shaping. Preferably, the pressure is applied by extruding the material through a die which may be maintained at the same temperature as that of the polymeric material. The article may also be used in engineering to develop gaskets for underwater use or as a tube or sleeve for sealing ruptured pipes; in electrical applications as a sleeve for sliding over electrical connectors; in medicine as a tube for sliding over limbs to immobilise broken bones and in vascular therapy as a tube or sleeve for sliding over arteries or for insertion into blood vessels or other body passages and cavities for opening up constrictions.
Use of high doses of acetyl salicylic acid is claimed to inhibit the proliferation of smooth muscle cells in the intima and/or media after vascular injury USE - The high doses of acetylsalicylic acid inhibit the proliferation of smooth muscle cells in the intima and/or media after vascular injury and inhibit the migration of smooth muscle cells from the media to the intima and inhibit the formation of an extracellular matrix and neointima formation (plaque formation). Esp. the high acetylsalicylic doses can be used to inhibit and treat arterial resterosis after angioplasty and thickening of the vessel walls after vascular surgery on arteries and veins. In an example human smooth muscle cells were trypsinised and cultivated in 1 ml MEM-EARL&#39;s medium contg. 10% human serum (as growth stimulant). After 8 days growth, the control gp. had 387000 cells, while a gp. which had received 150 mg/l acetyl/salicylic acid had 35250 cells. This corresponded to a 90% inhibition of the rate of proliferation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide improved autologous T-cell vaccines, and to provide a method for producing the vaccines.  &lt;P&gt;SOLUTION: The improved autologous T cell vaccines and a method for producing the vaccines are provided. The method for treating T cell-associated diseases such as multiple sclerosis and chronic rheumatoid arthritis by using the autologous T cell vaccine is provided. In one embodiment, a plurality of mononuclear cells containing T cell are obtained from peripheral blood (PBMC). In another embodiment, the plurality of mononuclear cells are obtained from cerebrospinal fluid (CSFMC). In one embodiment, the one or more multiple sclerosis-associated antigen is a myelin antigen selected from a group consisting of myelin basic protein, proteolipid lipoprotein, myelin oligodendrocyte glycoprotein and fragments thereof.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To obtain the titled remedy containing an antibiotic substance in stabilized form, and applicable easily and locally to the gingival space, by adding a tetracycline antibiotic to a anhydrous water-soluble ointment base obtained by mixing two kinds of polyethylene glycols having different molecular weights at a specific ratio. CONSTITUTION:The objective remedy for periodontosis is prepared by adding a tetracycline antibiotic (e.g. tetracycline, oxytetracycline, etc.) to an anhydrous water-soluble ointment base consisting of a mixture containing 40-90wt% polyethylene glycol having an average molecular weight of 400 and a polyethylene glycol solid at normal temperature and having an average molecular weight of &gt;=400. The participation of Gram-negative bacteria in the gingival space in the periodontosis has been clarified, and the local administration of a tetracycline antibiotic has been desired to prevent the problem of constitutional side effects. The antibiotic compounded to the above base is stabilized and releasable easily from the medicinal preparation. The released antibiotic remains in the gingival space for a long period.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a micro-particle zinc oxide dispersion affording a natural finish feeling with transparency and having excellent ultraviolet protecting effects in both the UVA and the UVB regions and good stability with time.  &lt;P&gt;SOLUTION: The micro-particle zinc oxide dispersion is characterized as dispersing micro-particle zinc oxide having 15-55 nm primary particle diameter into 70-140 nm average dispersed particle diameter in a hydrophobic dispersion medium. In the micro-particle zinc oxide dispersion, the content of the silicone oil is preferably 10-100 mass% based on the whole hydrophobic dispersion medium. A both terminal siliconated polyglycerol is further preferably contained as a dispersing agent in the micro-particle zinc oxide dispersion. The micro-particle zinc oxide dispersion can suitably be formulated in a cosmetic.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antimetabolic syndrome material having AMPK activating action and high safety.  &lt;P&gt;SOLUTION: The invention discloses an AMPK activation agent expected to have preventing and treating effect on metabolic syndromes such as obesity, hyperlipemia, hyperglycemia (diabetes) and hypertension. The AMPK activation agent contains extract of e.g. rosemary and/or sage. The activation of AMPK can be efficiently promoted by the use of the AMPK activation agent. The AMPK activation agent can increase AMPK activity extremely safely in vivo without accompanying side actions.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT